Why Medicaid cuts could be a ‘crisis’ for people with disabilities
If the new administration slashes federal Medicaid spending, millions of people with disabilities would be cut off from critical health care services.
Related Articles
FDA’s Troy Tazbaz returns to Oracle after a short stint shaping health AI rules
Troy Tazbaz, the outgoing director of the FDA’s digital health center, is returning to Oracle as a senior vice president.
Rare Disease Day 2024 – Faces of Rare | NORD
Faces of Rare: Join our online community wall campaign. Share your story, connect with others facing rare challenges. Unite for awareness!
Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
The ironic origin story behind Sloan Kettering
Sloan Kettering is one of the world’s leading cancer centers. It was founded by two men who created and sold leaded gasoline — a destructive,…
The ‘GRAS’ loophole lets untested additives into Americans’ food. Can RFK Jr. close it?
RFK Jr. wants to tackle the GRAS exemption, which allows companies to put chemicals in food without review by the FDA. Many have tried before…
Behind the scenes, Mass General Brigham fights Dana-Farber’s proposed hospital
A fight over the future of cancer care is playing out in a behind-the-scenes battle over Dana-Farber Cancer Institute’s proposed new hospital.
Rare Disease Day 2024 – Share an Event | NORD
Connect through our Rare Disease Day Events page. Share and discover community events. Unite for awareness and support. Join us in making a difference!
Is there an amyloid mafia? STAT readers weigh in
“Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to the editor this week.
Duchenne gene therapy from Solid Biosciences produces promising results in early study
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an early sign of promise
Duchenne gene therapy from Solid Biosciences produces promising results in early study
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an early sign of promise
